<DOC>
	<DOCNO>NCT02057705</DOCNO>
	<brief_summary>This prospective , non-interventional , longitudinal study natural history function approximately 60 patient MTM United States , Canada Europe . The duration study , include enrollment period , 36 month . Data study use characterize disease course MTM determine outcome measure best ass efficacy potential therapy .</brief_summary>
	<brief_title>Prospective , Longitudinal Study Natural History Functional Status Patients With Myotubular Myopathy ( MTM )</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Myopathies , Structural , Congenital</mesh_term>
	<criteria>Inclusion criterion : Patients age ( newborn include ) may participate . Patients 18 year age parent ( ) /legal guardian ( ) patient &lt; 18 year age must provide write informed consent prior participate study inform assent obtain minor least 7 year age require regulation . MTM result mutation MTM1 gene . Male symptomatic female . A symptomatic female define motor function assessment Motor Function Measure ( MFM ) North Star Ambulatory Assessment ( NSAA ) 80 % total score . Willing able comply protocol requirement procedure . Exclusion criterion : Other disease may significantly interfere assessment MTM clearly related disease . Currently enrol treatment study ; treatment experimental therapy pyridostigmine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MTM</keyword>
	<keyword>myotubular myopathy</keyword>
	<keyword>X-linked centronuclear myopathy</keyword>
	<keyword>inherited myopathy</keyword>
	<keyword>neuromuscular disease</keyword>
	<keyword>hypotonia</keyword>
	<keyword>genetic mutation</keyword>
</DOC>